New treatment for advanced esophageal cancer after past therapy
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have stage III to IV esophageal squamous cell carcinoma that can’t be cured with surgery or curative radiation (and not the mixed adenosquamous type)
- Have not had chemotherapy or other whole-body (systemic) cancer treatment before, or your cancer came back more than 6 months after prior treatment
- Have at least one measurable tumor spot on scans that has not already been treated locally (like radiation), or a prior radiation spot that clearly got worse and still meets scan rules
- Age 18 to 75, with overall strength score (ECOG) 0 to 1 and expected survival over 3 months
- Be able to provide tumor tissue for gene testing and PD-L1 testing, plus blood and mouth swabs as the study schedules require
- Have blood, liver, kidney, and clotting test results that meet the trial’s safety thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a combination of immunotherapy and a drug called anlotinib (which helps stop blood vessel growth to tumors) after surgery for esophageal cancer. If you had some cancer left after surgery and it spread to lymph nodes, this treatment might help prevent the cancer from coming back.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.